Terms: = Germ cell tumor AND CD74, ENSG00000019582, 972, protein 41, Ia-GAMMA, HLADG, DHLAG AND Treatment
29 results:
1. Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma.
Wang Q; Liu W; Zhou H; Lai W; Hu C; Dai Y; Li G; Zhang R; Zhao Y
Neoplasia; 2024 Feb; 48():100966. PubMed ID: 38237304
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of HASTE versus EPI-Based DWI for Retinoblastoma and Correlation with Prognostic Histopathologic Parameters.
Sharma M; Gupta A; Jana M; Kashyap S; Bakhshi S; Sharma S
AJNR Am J Neuroradiol; 2024 Feb; 45(2):198-204. PubMed ID: 38176729
[TBL] [Abstract] [Full Text] [Related]
3. Investigating the causal impact of gut microbiota on glioblastoma: a bidirectional Mendelian randomization study.
Zeng C; Zhang C; He C; Song H
BMC Genomics; 2023 Dec; 24(1):784. PubMed ID: 38110895
[TBL] [Abstract] [Full Text] [Related]
4. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract] [Full Text] [Related]
5. In vitro Evaluation of Selective Cytotoxic Activity of Chaerophyllum macropodum Boiss. on Cultured Human SH-SY5Y Neuroblastoma cells.
Çelikezen FÇ; Türkez H; Firat M; Arslan ME; Öner S
Neurotox Res; 2022 Oct; 40(5):1360-1368. PubMed ID: 35867270
[TBL] [Abstract] [Full Text] [Related]
6. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
[TBL] [Abstract] [Full Text] [Related]
7. tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract] [Full Text] [Related]
8. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract] [Full Text] [Related]
9. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract] [Full Text] [Related]
10. Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Yekedüz E; Dursun B; Aydın GÇ; Yazgan SC; Öztürk HH; Azap A; Utkan G; Ürün Y
J Oncol Pharm Pract; 2020 Jul; 26(5):1289-1294. PubMed ID: 32423324
[TBL] [Abstract] [Full Text] [Related]
11. Automated glioma grading on conventional MRI images using deep convolutional neural networks.
Zhuge Y; Ning H; Mathen P; Cheng JY; Krauze AV; Camphausen K; Miller RW
Med Phys; 2020 Jul; 47(7):3044-3053. PubMed ID: 32277478
[TBL] [Abstract] [Full Text] [Related]
12. Macrophage migration inhibitory factor-cd74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
[TBL] [Abstract] [Full Text] [Related]
13. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T.
Meissner JE; Korzowski A; Regnery S; Goerke S; Breitling J; Floca RO; Debus J; Schlemmer HP; Ladd ME; Bachert P; Adeberg S; Paech D
J Magn Reson Imaging; 2019 Oct; 50(4):1268-1277. PubMed ID: 30864193
[TBL] [Abstract] [Full Text] [Related]
14. Clival chordoma: long-term clinical outcome in a single center.
Zhou Y; Hu B; Wu Z; Cheng H; Dai M; Zhang B
Medicine (Baltimore); 2018 Sep; 97(36):e12207. PubMed ID: 30200131
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.
Thibouw D; Truc G; Bertaut A; Chevalier C; Aubignac L; Mirjolet C
J Neurooncol; 2018 Apr; 137(2):429-438. PubMed ID: 29374810
[TBL] [Abstract] [Full Text] [Related]
16. [Optic chiasm glioma in children: Endocrine disorders in 14 cases].
García García E; Márquez Vega C; Fajardo Cascos M; Venegas Moreno E; Soto Moreno A
Med Clin (Barc); 2016 May; 146(10):446-9. PubMed ID: 26971985
[TBL] [Abstract] [Full Text] [Related]
17. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
[TBL] [Abstract] [Full Text] [Related]
18. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic.
Watts CG; Cust AE; Menzies SW; Coates E; Mann GJ; Morton RL
JAMA Dermatol; 2015 Feb; 151(2):178-86. PubMed ID: 25389712
[TBL] [Abstract] [Full Text] [Related]
19. MIF Receptor cd74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas.
Zeiner PS; Preusse C; Blank AE; Zachskorn C; Baumgarten P; Caspary L; Braczynski AK; Weissenberger J; Bratzke H; Reiß S; Pennartz S; Winkelmann R; Senft C; Plate KH; Wischhusen J; Stenzel W; Harter PN; Mittelbronn M
Brain Pathol; 2015 Jul; 25(4):491-504. PubMed ID: 25175718
[TBL] [Abstract] [Full Text] [Related]
20. Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project.
Nardone B; Hammel JA; Raisch DW; Weaver LL; Schneider D; West DP
Br J Dermatol; 2014 May; 170(5):1170-2. PubMed ID: 24328939
[TBL] [Abstract] [Full Text] [Related]
[Next]
